Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Azitra, Inc.AZTR · Entity 7959 | Director · President and CEO | June 16, 2026 | June 18, 2026 |
| Vincerx Pharma, Inc.VINC · Entity 84409 | Director | May 23, 2024 | May 28, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Azitra, Inc.
Report date June 16, 2026 · Filed June 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 4,086,291 |
Reported balance
After 2026-06-16 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-16 · Conversion · Acquired 4,064,050 · Balance 4,086,291 F1: Each share of Series A Convertible Non-Redeemable Preferred Stock ("Series A Preferred Stock") automatically converted into 8,128.1 shares of common stock, for no additional consideration, at 5 p. m. Eastern Time on June 16, 2026, subject to the terms of the Certificate of Designations, Preferences and Rights of Series A Convertible Non-Redeemable Preferred Stock of Azitra, Inc. (the "Certificate of Designations") and subject to the applicable Beneficial Ownership Limitations (as defined in the Certificate of Designations). Each share of Series A Preferred Stock was sold together with a Series B Common Stock Purchase Warrant to purchase shares of common stock and a Series C Common Stock Purchase Warrant to purchase shares of common stock (collectively, a "Security"). The Securities were sold at a purchase price of $1,000.00 per Security to the Reporting Person. F2: Includes 22,241 Incentive Stock Options held by Mr. Salva and exercisable within 60 days of June 16, 2026. |
| Series A Convertible Non-Redeemable Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-06-16 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-16 · Conversion · Disposed 500 · Balance 0 F1: Each share of Series A Convertible Non-Redeemable Preferred Stock ("Series A Preferred Stock") automatically converted into 8,128.1 shares of common stock, for no additional consideration, at 5 p. m. Eastern Time on June 16, 2026, subject to the terms of the Certificate of Designations, Preferences and Rights of Series A Convertible Non-Redeemable Preferred Stock of Azitra, Inc. (the "Certificate of Designations") and subject to the applicable Beneficial Ownership Limitations (as defined in the Certificate of Designations). Each share of Series A Preferred Stock was sold together with a Series B Common Stock Purchase Warrant to purchase shares of common stock and a Series C Common Stock Purchase Warrant to purchase shares of common stock (collectively, a "Security"). The Securities were sold at a purchase price of $1,000.00 per Security to the Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share of Series A Convertible Non-Redeemable Preferred Stock ("Series A Preferred Stock") automatically converted into 8,128.1 shares of common stock, for no additional consideration, at 5 p. m. Eastern Time on June 16, 2026, subject to the terms of the Certificate of Designations, Preferences and Rights of Series A Convertible Non-Redeemable Preferred Stock of Azitra, Inc. (the "Certificate of Designations") and subject to the applicable Beneficial Ownership Limitations (as defined in the Certificate of Designations). Each share of Series A Preferred Stock was sold together with a Series B Common Stock Purchase Warrant to purchase shares of common stock and a Series C Common Stock Purchase Warrant to purchase shares of common stock (collectively, a "Security"). The Securities were sold at a purchase price of $1,000.00 per Security to the Reporting Person.
F2: Includes 22,241 Incentive Stock Options held by Mr. Salva and exercisable within 60 days of June 16, 2026.
Vincerx Pharma, Inc.
Report date May 23, 2024 · Filed May 28, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.70 · Expires 2034-05-22 | Direct | 15,000 |
Reported balance
After 2024-05-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-05-23 · Grant · Acquired 15,000 · Balance 15,000 F1: The option vests in full on the earlier of May 23, 2025, the next annual meeting of stockholders, or the consummation of a change of control, subject to the director's continued service. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests in full on the earlier of May 23, 2025, the next annual meeting of stockholders, or the consummation of a change of control, subject to the director's continued service.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 16, 2026 Filed Jun 18, 2026 20:30 UTC | Azitra, Inc. AZTR · Entity 7959 | ConversionSeries A Convertible Non-Redeemable Preferred Stock · Derivative | 500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-26-029345 · ownership.xml · derivative · entry 2 Salva Francisco D. · CIK 0001834051 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,064,050 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Convertible Non-Redeemable Preferred Stock ("Series A Preferred Stock") automatically converted into 8,128.1 shares of common stock, for no additional consideration, at 5 p. m. Eastern Time on June 16, 2026, subject to the terms of the Certificate of Designations, Preferences and Rights of Series A Convertible Non-Redeemable Preferred Stock of Azitra, Inc. (the "Certificate of Designations") and subject to the applicable Beneficial Ownership Limitations (as defined in the Certificate of Designations). Each share of Series A Preferred Stock was sold together with a Series B Common Stock Purchase Warrant to purchase shares of common stock and a Series C Common Stock Purchase Warrant to purchase shares of common stock (collectively, a "Security"). The Securities were sold at a purchase price of $1,000.00 per Security to the Reporting Person. F1 · price: Each share of Series A Convertible Non-Redeemable Preferred Stock ("Series A Preferred Stock") automatically converted into 8,128.1 shares of common stock, for no additional consideration, at 5 p. m. Eastern Time on June 16, 2026, subject to the terms of the Certificate of Designations, Preferences and Rights of Series A Convertible Non-Redeemable Preferred Stock of Azitra, Inc. (the "Certificate of Designations") and subject to the applicable Beneficial Ownership Limitations (as defined in the Certificate of Designations). Each share of Series A Preferred Stock was sold together with a Series B Common Stock Purchase Warrant to purchase shares of common stock and a Series C Common Stock Purchase Warrant to purchase shares of common stock (collectively, a "Security"). The Securities were sold at a purchase price of $1,000.00 per Security to the Reporting Person. F1 · derivative.exercise_date: Each share of Series A Convertible Non-Redeemable Preferred Stock ("Series A Preferred Stock") automatically converted into 8,128.1 shares of common stock, for no additional consideration, at 5 p. m. Eastern Time on June 16, 2026, subject to the terms of the Certificate of Designations, Preferences and Rights of Series A Convertible Non-Redeemable Preferred Stock of Azitra, Inc. (the "Certificate of Designations") and subject to the applicable Beneficial Ownership Limitations (as defined in the Certificate of Designations). Each share of Series A Preferred Stock was sold together with a Series B Common Stock Purchase Warrant to purchase shares of common stock and a Series C Common Stock Purchase Warrant to purchase shares of common stock (collectively, a "Security"). The Securities were sold at a purchase price of $1,000.00 per Security to the Reporting Person. F1 · derivative.expiration_date: Each share of Series A Convertible Non-Redeemable Preferred Stock ("Series A Preferred Stock") automatically converted into 8,128.1 shares of common stock, for no additional consideration, at 5 p. m. Eastern Time on June 16, 2026, subject to the terms of the Certificate of Designations, Preferences and Rights of Series A Convertible Non-Redeemable Preferred Stock of Azitra, Inc. (the "Certificate of Designations") and subject to the applicable Beneficial Ownership Limitations (as defined in the Certificate of Designations). Each share of Series A Preferred Stock was sold together with a Series B Common Stock Purchase Warrant to purchase shares of common stock and a Series C Common Stock Purchase Warrant to purchase shares of common stock (collectively, a "Security"). The Securities were sold at a purchase price of $1,000.00 per Security to the Reporting Person. Read SEC document |
| June 16, 2026 Filed Jun 18, 2026 20:30 UTC | Azitra, Inc. AZTR · Entity 7959 | ConversionCommon Stock | 4,064,050 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-26-029345 · ownership.xml · nonDerivative · entry 1 Salva Francisco D. · CIK 0001834051 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,086,291 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series A Convertible Non-Redeemable Preferred Stock ("Series A Preferred Stock") automatically converted into 8,128.1 shares of common stock, for no additional consideration, at 5 p. m. Eastern Time on June 16, 2026, subject to the terms of the Certificate of Designations, Preferences and Rights of Series A Convertible Non-Redeemable Preferred Stock of Azitra, Inc. (the "Certificate of Designations") and subject to the applicable Beneficial Ownership Limitations (as defined in the Certificate of Designations). Each share of Series A Preferred Stock was sold together with a Series B Common Stock Purchase Warrant to purchase shares of common stock and a Series C Common Stock Purchase Warrant to purchase shares of common stock (collectively, a "Security"). The Securities were sold at a purchase price of $1,000.00 per Security to the Reporting Person. F2 · balance_after: Includes 22,241 Incentive Stock Options held by Mr. Salva and exercisable within 60 days of June 16, 2026. Read SEC document |
| April 20, 2026 Filed Apr 22, 2026 21:30 UTC | Azitra, Inc. AZTR · Entity 7959 | GrantStock Options (Right To Buy) · Derivative | 220,879 | $0.00 Strike: $0.21 | $0.00 |
DisclosureSEC source: 0001493152-26-018596 · ownership.xml · derivative · entry 1 Salva Francisco D. · CIK 0001834051 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 220,879 Underlying: Common Stock · 220,879 shares Expires 2036-04-20 F1 · derivative.exercise_date: 1/3rd of the total number of shares of the Company's common stock subject to the option shall vest on the one year anniversary of the date of issuance, the Vesting Commencement Date, and 1/36th of the total number of shares of the Company's common stock subject to the option will vest each calendar month thereafter for the next two years, on the same day of the month as the Vesting Commencement Date. Read SEC document |
| March 18, 2026 Filed Mar 20, 2026 20:30 UTC | Azitra, Inc. AZTR · Entity 7959 | PurchaseSeries C Warrants · Derivative | 4,064,050 | Not disclosed Strike: $0.12 | Not disclosed |
DisclosureSEC source: 0001493152-26-011858 · ownership.xml · derivative · entry 3 Salva Francisco D. · CIK 0001834051 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,064,050 Underlying: Common Stock · 4,064,050 shares Expires not disclosed F3 · price: The Series C Warrants are exercisable upon stockholder approval and will terminate, subject to certain exceptions, upon the 30th calendar day following the date on which Azitra, Inc. publicly announces data from its planned human cosmetic study testing the effect of the filaggrin technology. F3 · derivative.exercise_date: The Series C Warrants are exercisable upon stockholder approval and will terminate, subject to certain exceptions, upon the 30th calendar day following the date on which Azitra, Inc. publicly announces data from its planned human cosmetic study testing the effect of the filaggrin technology. F3 · derivative.expiration_date: The Series C Warrants are exercisable upon stockholder approval and will terminate, subject to certain exceptions, upon the 30th calendar day following the date on which Azitra, Inc. publicly announces data from its planned human cosmetic study testing the effect of the filaggrin technology. Read SEC document |
| March 18, 2026 Filed Mar 20, 2026 20:30 UTC | Azitra, Inc. AZTR · Entity 7959 | PurchaseSeries B Warrants · Derivative | 4,064,050 | Not disclosed Strike: $0.12 | Not disclosed |
DisclosureSEC source: 0001493152-26-011858 · ownership.xml · derivative · entry 2 Salva Francisco D. · CIK 0001834051 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,064,050 Underlying: Common Stock · 4,064,050 shares Expires not disclosed F1 · price: The Series A Preferred Stock has stated value of $1,000.00 per share. Each share of Series A Preferred Stock automatically converts into 8,128.1 shares of Common Stock, subject to adjustment from time to time in accordance with its Certificate of Designations, Preferences, as of 5:00 p.m. Eastern time on the 1st business day after the date that the Issuer's stockholders have approved each of (A) an increase in the number of authorized shares of the Issuer's Common Stock to enable the Issuer to issue all of the shares of Common Stock that are issuable upon the conversion of the Series A Preferred Stock and (B) the conversion of the Series A Preferred Stock into Common Stock in accordance with the listing rules of the applicable trading market, and subject to the Issuer filing an amendment to the Certificate of Incorporation with the Secretary of State of the State of Delaware evidencing such stockholder approval. The Series A Preferred Stock has no expiration date. F2 · derivative.exercise_date: The Series B Warrants are exercisable upon stockholder approval and will terminate 18 months following the date of stockholder approval. F2 · derivative.expiration_date: The Series B Warrants are exercisable upon stockholder approval and will terminate 18 months following the date of stockholder approval. Read SEC document |
| March 18, 2026 Filed Mar 20, 2026 20:30 UTC | Azitra, Inc. AZTR · Entity 7959 | PurchaseSeries A Convertible Non-Redeemable Preferred Stock · Derivative | 500 | Not disclosed Strike: $0.12 | Not disclosed |
DisclosureSEC source: 0001493152-26-011858 · ownership.xml · derivative · entry 1 Salva Francisco D. · CIK 0001834051 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 500 Underlying: Common Stock · 4,064,050 shares Expires not disclosed F1 · price: The Series A Preferred Stock has stated value of $1,000.00 per share. Each share of Series A Preferred Stock automatically converts into 8,128.1 shares of Common Stock, subject to adjustment from time to time in accordance with its Certificate of Designations, Preferences, as of 5:00 p.m. Eastern time on the 1st business day after the date that the Issuer's stockholders have approved each of (A) an increase in the number of authorized shares of the Issuer's Common Stock to enable the Issuer to issue all of the shares of Common Stock that are issuable upon the conversion of the Series A Preferred Stock and (B) the conversion of the Series A Preferred Stock into Common Stock in accordance with the listing rules of the applicable trading market, and subject to the Issuer filing an amendment to the Certificate of Incorporation with the Secretary of State of the State of Delaware evidencing such stockholder approval. The Series A Preferred Stock has no expiration date. F1 · derivative.exercise_date: The Series A Preferred Stock has stated value of $1,000.00 per share. Each share of Series A Preferred Stock automatically converts into 8,128.1 shares of Common Stock, subject to adjustment from time to time in accordance with its Certificate of Designations, Preferences, as of 5:00 p.m. Eastern time on the 1st business day after the date that the Issuer's stockholders have approved each of (A) an increase in the number of authorized shares of the Issuer's Common Stock to enable the Issuer to issue all of the shares of Common Stock that are issuable upon the conversion of the Series A Preferred Stock and (B) the conversion of the Series A Preferred Stock into Common Stock in accordance with the listing rules of the applicable trading market, and subject to the Issuer filing an amendment to the Certificate of Incorporation with the Secretary of State of the State of Delaware evidencing such stockholder approval. The Series A Preferred Stock has no expiration date. F1 · derivative.expiration_date: The Series A Preferred Stock has stated value of $1,000.00 per share. Each share of Series A Preferred Stock automatically converts into 8,128.1 shares of Common Stock, subject to adjustment from time to time in accordance with its Certificate of Designations, Preferences, as of 5:00 p.m. Eastern time on the 1st business day after the date that the Issuer's stockholders have approved each of (A) an increase in the number of authorized shares of the Issuer's Common Stock to enable the Issuer to issue all of the shares of Common Stock that are issuable upon the conversion of the Series A Preferred Stock and (B) the conversion of the Series A Preferred Stock into Common Stock in accordance with the listing rules of the applicable trading market, and subject to the Issuer filing an amendment to the Certificate of Incorporation with the Secretary of State of the State of Delaware evidencing such stockholder approval. The Series A Preferred Stock has no expiration date. Read SEC document |
| December 19, 2025 Filed Dec 22, 2025 22:28 UTC | Azitra, Inc. AZTR · Entity 7959 | GrantStock Options (Right To Buy) · Derivative | 59,309 | $0.00 Strike: $0.30 | $0.00 |
DisclosureSEC source: 0001493152-25-028846 · ownership.xml · derivative · entry 1 Salva Francisco D. · CIK 0001834051 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,309 Underlying: Common Stock · 59,309 shares Expires 2035-12-19 F1 · derivative.exercise_date: 25% of the shares of the Company's Common Stock subject to the Option shall vest on the date of issuance, the Vesting Commencement Date, and the remaining balance shall vest in equal monthly installments over the next 36 months of continuous service thereafter. Read SEC document |
| May 23, 2024 Filed May 28, 2024 16:38 UTC | Vincerx Pharma, Inc. VINC · Entity 84409 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $0.70 | $0.00 |
DisclosureSEC source: 0000950170-24-065295 · ownership.xml · derivative · entry 1 Salva Francisco D. · CIK 0001834051 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2034-05-22 F1 · derivative.exercise_date: The option vests in full on the earlier of May 23, 2025, the next annual meeting of stockholders, or the consummation of a change of control, subject to the director's continued service. Read SEC document |
| February 13, 2024 Filed Feb 16, 2024 01:38 UTC | Azitra, Inc. AZTR · Entity 7959 | PurchaseCommon Stock | 333,300 | $0.30 | $99,990.00 |
DisclosureSEC source: 0001493152-24-006912 · ownership.xml · nonDerivative · entry 1 Salva Francisco D. · CIK 0001834051 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 338,300 Read SEC document |
| June 21, 2023 Filed Jun 24, 2023 00:39 UTC | Azitra, Inc. AZTR · Entity 7959 | GrantCommon Stock | 5,000 | $5.00 | $25,000.00 |
DisclosureSEC source: 0001493152-23-022316 · ownership.xml · nonDerivative · entry 1 Salva Francisco D. · CIK 0001834051 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 Read SEC document |
| May 25, 2023 Filed May 30, 2023 16:05 UTC | Vincerx Pharma, Inc. VINC · Entity 84409 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $1.62 | $0.00 |
DisclosureSEC source: 0000899243-23-014050 · doc4.xml · derivative · entry 1 Salva Francisco D. · CIK 0001834051 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2033-05-24 F1 · derivative.exercise_date: The option vests in full on the earlier of May 25, 2024, the next annual meeting of stockholders, or the consummation of a change of control, subject to the director's continued service. Read SEC document |
| May 26, 2022 Filed May 31, 2022 16:06 UTC | Vincerx Pharma, Inc. VINC · Entity 84409 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $1.61 | $0.00 |
DisclosureSEC source: 0000899243-22-020151 · doc4.xml · derivative · entry 1 Salva Francisco D. · CIK 0001834051 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2032-05-25 F1 · derivative.exercise_date: The option vests in full on the earlier of May 26, 2023, the next annual meeting of stockholders or the consummation of a change of control, subject to the director's continued service. Read SEC document |
| May 13, 2021 Filed May 14, 2021 17:23 UTC | Vincerx Pharma, Inc. VINC · Entity 84409 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $16.34 | $0.00 |
DisclosureSEC source: 0000899243-21-019558 · doc4.xml · derivative · entry 1 Salva Francisco D. · CIK 0001834051 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2031-05-12 F1 · derivative.exercise_date: The option vests in full on the earlier of May 13, 2022, the next annual meeting of stockholders or the consummation of a change of control, subject to the director's continued service. Read SEC document |
| December 23, 2020 Filed Dec 28, 2020 21:26 UTC | Vincerx Pharma, Inc. VINC · Entity 84409 | GrantStock Option (right to buy) · Derivative | 6,667 | $0.00 Strike: $19.00 | $0.00 |
DisclosureSEC source: 0000899243-20-035390 · doc4.xml · derivative · entry 1 Salva Francisco D. · CIK 0001834051 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,667 Underlying: Common Stock · 6,667 shares Expires 2030-12-23 F1 · derivative.exercise_date: The option vests in full on the earlier of December 23, 2021, the next annual meeting of stockholders or the consummation of a change of control, subject to the director's continued service. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.